Terms: = Breast cancer AND BCL9L, BCL9-2, 283149, ENSG00000186174, DLNB11 AND Treatment
3 results:
1. BCL9/bcl9l promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
Wang X; Feng M; Xiao T; Guo B; Liu D; Liu C; Pei J; Liu Q; Xiao Y; Rosin-Arbesfeld R; Shi Y; Zhou Y; Yang M; Feng YX; Jiang Y; Shao Z; Yu K; Zhu D
Oncogene; 2021 Apr; 40(16):2982-2997. PubMed ID: 33767438
[TBL] [Abstract] [Full Text] [Related]
2. Single-walled carbon nanotubes functionalized with aptamer and piperazine-polyethylenimine derivative for targeted siRNA delivery into breast cancer cells.
Mohammadi M; Salmasi Z; Hashemi M; Mosaffa F; Abnous K; Ramezani M
Int J Pharm; 2015 May; 485(1-2):50-60. PubMed ID: 25712164
[TBL] [Abstract] [Full Text] [Related]
3. The bcl9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis.
Zatula N; Wiese M; Bunzendahl J; Birchmeier W; Perske C; Bleckmann A; Brembeck FH
Oncotarget; 2014 Aug; 5(16):6770-87. PubMed ID: 25149534
[TBL] [Abstract] [Full Text] [Related]
